Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer.

Cascone T, Sepesi B, Lin H, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella F, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Reza MJ, Rice D, Behren C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV.

Clin Cancer Res. 2020 Mar 19. pii: clincanres.4180.2019. doi: 10.1158/1078-0432.CCR-19-4180. [Epub ahead of print]

2.

Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer.

Parra ER, Jiang M, Machado-Rugolo J, Yaegashi LB, Prieto T, Farhat C, de Sá VK, Nagai MA, de Lima VCC, Takagaki T, Terra R, Fabro AT, Capelozzi VL.

Arch Pathol Lab Med. 2020 Mar 9. doi: 10.5858/arpa.2019-0419-OA. [Epub ahead of print]

PMID:
32150457
3.

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.

Overman M, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, Mettu NB, Parra ER, Benson AB, Lopez CD, Munugalavadla V, Patel P, Tao L, Neelapu S, Maitra A.

J Immunother Cancer. 2020 Feb;8(1). pii: e000587. doi: 10.1136/jitc-2020-000587.

4.

Comprehensive T cell repertoire characterization of non-small cell lung cancer.

Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J.

Nat Commun. 2020 Jan 30;11(1):603. doi: 10.1038/s41467-019-14273-0.

5.

Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies.

Parra ER, Jiang M, Solis L, Mino B, Laberiano C, Hernandez S, Gite S, Verma A, Tetzlaff M, Haymaker C, Tamegnon A, Rodriguez-Canales J, Hoyd C, Bernachez C, Wistuba I.

Cancers (Basel). 2020 Jan 21;12(2). pii: E255. doi: 10.3390/cancers12020255. Review.

6.

Computational staining of pathology images to study the tumor microenvironment in lung cancer.

Wang S, Rong R, Yang DM, Fujimoto J, Yan S, Cai L, Yang L, Luo D, Behrens C, Parra ER, Yao B, Xu L, Wang T, Zhan X, Wistuba II, Minna J, Xie Y, Xiao G.

Cancer Res. 2020 Jan 8. pii: canres.1629.2019. doi: 10.1158/0008-5472.CAN-19-1629. [Epub ahead of print]

PMID:
31915129
7.

Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.

Keung EZ, Burgess M, Salazar R, Parra ER, Rodrigues-Canales J, Bolejack V, Van Tine BA, Schuetze SM, Attia S, Riedel RF, Hu J, Okuno SH, Priebat DA, Movva S, Davis LE, Reed DR, Reuben A, Roland CL, Reinke D, Lazar AJ, Wang WL, Wargo JA, Tawbi HA.

Clin Cancer Res. 2020 Mar 15;26(6):1258-1266. doi: 10.1158/1078-0432.CCR-19-1824. Epub 2020 Jan 3.

PMID:
31900276
8.

High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.

Massarelli E, Lam VK, Parra ER, Rodriguez-Canales J, Behrens C, Diao L, Wang J, Blando J, Byers LA, Yanamandra N, Brett S, Morley P, Sharma P, Allison J, Wistuba II, Heymach JV.

J Immunother Cancer. 2019 Dec 16;7(1):351. doi: 10.1186/s40425-019-0827-2.

9.

Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer.

Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T, Roarty E, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Sepesi B.

Ann Thorac Surg. 2020 Feb;109(2):358-366. doi: 10.1016/j.athoracsur.2019.08.029. Epub 2019 Sep 21.

PMID:
31550464
10.

Multiplex Immunofluorescence Assays.

Francisco-Cruz A, Parra ER, Tetzlaff MT, Wistuba II.

Methods Mol Biol. 2020;2055:467-495. doi: 10.1007/978-1-4939-9773-2_22.

PMID:
31502166
11.

CD4+CD69+ T cells and CD4+CD25+FoxP3+ Treg cells imbalance in peripheral blood, spleen and peritoneal lavage from pristane-induced systemic lupus erythematosus (SLE) mice.

Peixoto TV, Carrasco S, Botte DAC, Catanozi S, Parra ER, Lima TM, Ugriumov N, Soriano FG, de Mello SBV, Rodrigues CM, Goldenstein-Schainberg C.

Adv Rheumatol. 2019 Jul 24;59(1):30. doi: 10.1186/s42358-019-0072-x.

PMID:
31340848
12.

Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer.

Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons D, Zhang J, Lang FF, Luthra R, Lee JJ, Moran C, Huse JT, Kadara H, Wistuba II.

Ann Oncol. 2019 Sep 1;30(9):1521-1530. doi: 10.1093/annonc/mdz207.

PMID:
31282941
13.

Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.

Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy MC, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff MB, Zhang J, Vaporciyan AA, Pass H, Swisher SG, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal PA, Su D, Zhang J.

Nat Commun. 2019 Jul 5;10(1):2978. doi: 10.1038/s41467-019-10877-8.

14.

Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer.

Mitchell KG, Parra ER, Nelson DB, Zhang J, Wistuba II, Fujimoto J, Roth JA, Antonoff MB; MD Anderson Lung Cancer Immune Microenvironment Working Group.

J Thorac Cardiovasc Surg. 2019 Sep;158(3):911-919.e6. doi: 10.1016/j.jtcvs.2019.04.084. Epub 2019 May 17.

PMID:
31235357
15.

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.

Soundararajan R, Fradette JJ, Konen JM, Moulder S, Zhang X, Gibbons DL, Varadarajan N, Wistuba II, Tripathy D, Bernatchez C, Byers LA, Chang JT, Contreras A, Lim B, Parra ER, Roarty EB, Wang J, Yang F, Barton M, Rosen JM, Mani SA.

Cancers (Basel). 2019 May 24;11(5). pii: E714. doi: 10.3390/cancers11050714. Review.

16.

B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density.

Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres-Cabala CA, Efstathiou E, Hoang AG, Wong MK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba I, Tetzlaff MT.

Clin Cancer Res. 2019 Jun 1;25(11):3455-3467. doi: 10.1158/1078-0432.CCR-18-2355. Epub 2019 Feb 26.

PMID:
30808776
17.

State-of-the-Art of Profiling Immune Contexture in the Era of Multiplexed Staining and Digital Analysis to Study Paraffin Tumor Tissues.

Parra ER, Francisco-Cruz A, Wistuba II.

Cancers (Basel). 2019 Feb 20;11(2). pii: E247. doi: 10.3390/cancers11020247. Review.

18.

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens.

Surace M, DaCosta K, Huntley A, Zhao W, Bagnall C, Brown C, Wang C, Roman K, Cann J, Lewis A, Steele K, Rebelatto M, Parra ER, Hoyt CC, Rodriguez-Canales J.

J Vis Exp. 2019 Jan 21;(143). doi: 10.3791/58390.

PMID:
30735177
19.

Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR.

Nat Med. 2019 Jan;25(1):188. doi: 10.1038/s41591-018-0305-2.

PMID:
30479380
20.

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR.

Nat Med. 2018 Dec;24(12):1804-1808. doi: 10.1038/s41591-018-0238-9. Epub 2018 Nov 12. Erratum in: Nat Med. 2018 Nov 27;:.

21.

Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer.

Machado-Rugolo J, Fabro AT, Ascheri D, Farhat C, Ab'Saber AM, de Sá VK, Nagai MA, Takagaki T, Terra R, Parra ER, Capelozzi VL.

Hum Pathol. 2019 Jan;83:177-191. doi: 10.1016/j.humpath.2018.08.026. Epub 2018 Sep 13.

PMID:
30218756
22.

Histomorphometric evaluation of the Ki-67 proliferation rate and CD34 microvascular and D2-40 lymphovascular densities drives the pulmonary typical carcinoid outcome.

de Vilhena AF, das Neves Pereira JC, Parra ER, Balancin ML, Ab Saber A, Martins V, Farhat C, Abrantes MM, de Campos JRM, Tedde ML, Takagaki T, Capelozzi VL.

Hum Pathol. 2018 Nov;81:201-210. doi: 10.1016/j.humpath.2018.07.007. Epub 2018 Jul 18.

PMID:
30031097
23.

A Functional Spatial Analysis Platform for Discovery of Immunological Interactions Predictive of Low-Grade to High-Grade Transition of Pancreatic Intraductal Papillary Mucinous Neoplasms.

Barua S, Solis L, Parra ER, Uraoka N, Jiang M, Wang H, Rodriguez-Canales J, Wistuba I, Maitra A, Sen S, Rao A.

Cancer Inform. 2018 Jun 28;17:1176935118782880. doi: 10.1177/1176935118782880. eCollection 2018. Review.

24.

Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.

Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN Jr, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II.

J Immunother Cancer. 2018 Jun 6;6(1):48. doi: 10.1186/s40425-018-0368-0.

25.

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV.

Cancer Discov. 2018 Jul;8(7):822-835. doi: 10.1158/2159-8290.CD-18-0099. Epub 2018 May 17.

26.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS.

Ann Oncol. 2018 Apr 1;29(4):1072. doi: 10.1093/annonc/mdx062. No abstract available.

27.

Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.

Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach JV, Moran C, Zhang J, Lee J, Rodriguez-Canales J, Gibbons D, Wistuba II.

J Thorac Oncol. 2018 Jun;13(6):779-791. doi: 10.1016/j.jtho.2018.03.002. Epub 2018 Mar 8.

28.

Comprehensive analysis of immune, extracellular matrices and pathogens profile in lung granulomatosis of unexplained etiology.

da Costa Souza P, Dondo PS, Souza G, Lopes D, Moscardi M, de Miranda Martinho V, de Mattos Lourenço RD, Prieto T, Balancin ML, Assato AK, Teodoro WR, Rodrigues S, Lima M, Castellano MV, Coletta E, Parra ER, Capelozzi VL.

Hum Pathol. 2018 May;75:104-115. doi: 10.1016/j.humpath.2018.01.018. Epub 2018 Apr 16.

PMID:
29410258
29.

Novel Technology to Assess Programmed Death-Ligand 1 Expression by Multiplex Immunofluorescence and Image Analysis.

Parra ER.

Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):e22-e24. doi: 10.1097/PAI.0000000000000610. No abstract available.

PMID:
29189262
30.

The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells.

Parra ER, Villalobos P, Rodriguez-Canales J.

Appl Immunohistochem Mol Morphol. 2019 Apr;27(4):287-294. doi: 10.1097/PAI.0000000000000602.

PMID:
29135534
31.

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues.

Parra ER, Uraoka N, Jiang M, Cook P, Gibbons D, Forget MA, Bernatchez C, Haymaker C, Wistuba II, Rodriguez-Canales J.

Sci Rep. 2017 Oct 17;7(1):13380. doi: 10.1038/s41598-017-13942-8.

32.

4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

Sakellariou-Thompson D, Forget MA, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C.

Clin Cancer Res. 2017 Dec 1;23(23):7263-7275. doi: 10.1158/1078-0432.CCR-17-0831. Epub 2017 Sep 25.

33.

TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN Jr, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J.

Cancer Discov. 2017 Oct;7(10):1088-1097. doi: 10.1158/2159-8290.CD-17-0256. Epub 2017 Jul 21.

34.

Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.

Parra ER, Villalobos P, Mino B, Rodriguez-Canales J.

Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):83-93. doi: 10.1097/PAI.0000000000000531.

35.

Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.

Dalvi MP, Wang L, Zhong R, Kollipara RK, Park H, Bayo J, Yenerall P, Zhou Y, Timmons BC, Rodriguez-Canales J, Behrens C, Mino B, Villalobos P, Parra ER, Suraokar M, Pataer A, Swisher SG, Kalhor N, Bhanu NV, Garcia BA, Heymach JV, Coombes K, Xie Y, Girard L, Gazdar AF, Kittler R, Wistuba II, Minna JD, Martinez ED.

Cell Rep. 2017 May 23;19(8):1669-1684. doi: 10.1016/j.celrep.2017.04.077.

36.

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II.

Ann Oncol. 2017 Jan 1;28(1):83-89. doi: 10.1093/annonc/mdw437.

37.

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up.

Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS.

Ann Oncol. 2017 Jan 1;28(1):75-82. doi: 10.1093/annonc/mdw436. Erratum in: Ann Oncol. 2018 Apr 1;29(4):1072.

38.

Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.

Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II.

Clin Cancer Res. 2016 Dec 15;22(24):6278-6289. Epub 2016 Jun 1.

39.

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA.

Oncoimmunology. 2016 Feb 2;5(3):e1136044. eCollection 2016 Mar.

40.

Intranasal Administration of Type V Collagen Reduces Lung Carcinogenesis through Increasing Endothelial and Epithelial Apoptosis in a Urethane-Induced Lung Tumor Model.

Parra ER, Alveno RA, Faustino CB, Corrêa PY, Vargas CM, de Morais J, Rangel MP, Velosa AP, Fabro AT, Teodoro WR, Capelozzi VL.

Arch Immunol Ther Exp (Warsz). 2016 Aug;64(4):321-9. doi: 10.1007/s00005-016-0390-1. Epub 2016 Mar 28.

PMID:
27020095
41.

Early type I collagen deposition is associated with prognosis in biliary atresia.

Longo-Santos LR, Teodoro WR, de Mello ES, Velosa AP, Parra ER, Capelozzi VL, Tannuri U.

J Pediatr Surg. 2016 Mar;51(3):379-85. doi: 10.1016/j.jpedsurg.2015.08.061. Epub 2015 Sep 15.

PMID:
26452701
42.

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.

Mak MP, Tong P, Diao L, Cardnell RJ, Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J, Wistuba II, Heymach JV, Weinstein JN, Coombes KR, Wang J, Byers LA.

Clin Cancer Res. 2016 Feb 1;22(3):609-20. doi: 10.1158/1078-0432.CCR-15-0876. Epub 2015 Sep 29.

43.

Caryocar brasiliense camb protects against genomic and oxidative damage in urethane-induced lung carcinogenesis.

Colombo NB, Rangel MP, Martins V, Hage M, Gelain DP, Barbeiro DF, Grisolia CK, Parra ER, Capelozzi VL.

Braz J Med Biol Res. 2015 Sep;48(9):852-62. doi: 10.1590/1414-431X20154467. Epub 2015 Jul 21.

44.

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV.

Cancer Discov. 2015 Aug;5(8):860-77. doi: 10.1158/2159-8290.CD-14-1236. Epub 2015 Jun 11.

45.

Unusual remodeling of the hyalinization band in vulval lichen sclerosus by type V collagen and ECM 1 protein.

Godoy CA, Teodoro WR, Velosa AP, Garippo AL, Eher EM, Parra ER, Sotto MN, Capelozzi VL.

Clinics (Sao Paulo). 2015 May;70(5):356-62. doi: 10.6061/clinics/2015(05)09. Epub 2015 May 1.

46.

Tissue hyaluronan expression, as reflected in the sputum of lung cancer patients, is an indicator of malignancy.

Rangel MP, de Sá VK, Martins V, Martins JR, Parra ER, Mendes A, Andrade PC, Reis RM, Longatto-Filho A, Oliveira CZ, Takagaki T, Carraro DM, Nader HB, Capelozzi VL.

Braz J Med Biol Res. 2015 Jun;48(6):557-67. doi: 10.1590/1414-431X20144300. Epub 2015 May 8.

47.

Methylene blue attenuates ischemia--reperfusion injury in lung transplantation.

Abreu Mda M, Pazetti R, Almeida FM, Correia AT, Parra ER, Silva LP, Vieira RP, Pêgo-Fernandes PM, Jatene FB.

J Surg Res. 2014 Dec;192(2):635-41. doi: 10.1016/j.jss.2014.07.043. Epub 2014 Jul 24.

PMID:
25151469
48.

Usual interstitial pneumonia and smoking-related interstitial fibrosis display epithelial to mesenchymal transition in fibroblastic foci.

Fabro AT, Minatel IO, Rangel MP, Halbwedl I, Parra ER, Capelozzi VL, Popper H.

Respir Med. 2014 Sep;108(9):1377-86. doi: 10.1016/j.rmed.2014.06.008. Epub 2014 Jul 17.

49.

Modeling pulmonary fibrosis by abnormal expression of telomerase/apoptosis/collagen V in experimental usual interstitial pneumonia.

Parra ER, Pincelli MS, Teodoro WR, Velosa AP, Martins V, Rangel MP, Barbas-Filho JV, Capelozzi VL.

Braz J Med Biol Res. 2014 Jul;47(7):567-75. Epub 2014 Jun 4.

50.

Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis.

Christmann RB, Sampaio-Barros P, Stifano G, Borges CL, de Carvalho CR, Kairalla R, Parra ER, Spira A, Simms R, Capellozzi VL, Lafyatis R.

Arthritis Rheumatol. 2014 Mar;66(3):714-25. doi: 10.1002/art.38288.

Supplemental Content

Loading ...
Support Center